Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.

Published on Mar 3, 2021in PLOS Medicine10.5
· DOI :10.1371/JOURNAL.PMED.1003415
María Elvira Balcells10
Estimated H-index: 10
(UC: Pontifical Catholic University of Chile),
Luis Rojas10
Estimated H-index: 10
(UC: Pontifical Catholic University of Chile)
+ 29 AuthorsBruno Nervi14
Estimated H-index: 14
(UC: Pontifical Catholic University of Chile)
Background Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression. Methods and findings The study was an open-label, single-center randomized clinical trial performed in an academic medical center in Santiago, Chile, from May 10, 2020, to July 18, 2020, with final follow-up until August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted of immediate CP (early plasma group) versus no CP unless developing prespecified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days, or death. The key secondary outcomes included time to respiratory failure, days of mechanical ventilation, hospital length of stay, mortality at 30 days, and SARS-CoV-2 real-time PCR clearance rate. Of 58 randomized patients (mean age, 65.8 years; 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We failed to find benefit in the primary outcome (32.1% versus 33.3%, odds ratio [OR] 0.95, 95% CI 0.32-2.84, p > 0.999) in the early versus deferred CP group. The in-hospital mortality rate was 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17 p = 0.246), mechanical ventilation 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17, p = 0.246), and prolonged hospitalization 21.4% versus 30.0% (OR 0.64, 95% CI, 0.19-2.10, p = 0.554) in the early versus deferred CP group, respectively. The viral clearance rate on day 3 (26% versus 8%, p = 0.204) and day 7 (38% versus 19%, p = 0.374) did not differ between groups. Two patients experienced serious adverse events within 6 hours after plasma transfusion. The main limitation of this study is the lack of statistical power to detect a smaller but clinically relevant therapeutic effect of CP, as well as not having confirmed neutralizing antibodies in donor before plasma infusion. Conclusions In the present study, we failed to find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration. Trial registration NCT04375098.
📖 Papers frequently viewed together
12 Citations
13 Authors (Bihariesingh R, ..., Nierich A)
3 Citations
#1Carolina Beltrán-Pavez (University of Chile)H-Index: 3
#2Sebastián Riquelme-Barrios (University of Chile)H-Index: 3
Last. Ricardo Soto-Rifo (University of Chile)H-Index: 18
view all 20 authors...
Chile has one of the worst numbers worldwide in terms of SARS-CoV-2 positive cases and COVID-19-related deaths per million inhabitants; thus, characterization of neutralizing antibody (NAb) responses in the general population is critical to understanding of immunity at the local level. Given our inability to perform massive classical neutralization assays due to the scarce availability of BSL-3 facilities in the country, we developed and fully characterized an HIV-based SARS-CoV-2 pseudotype, wh...
4 CitationsSource
#1Fabian Schmidt (Rockefeller University)H-Index: 18
#2Yiska Weisblum (Rockefeller University)H-Index: 16
Last. Paul D. Bieniasz (Rockefeller University)H-Index: 84
view all 21 authors...
The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate v...
186 CitationsSource
#1Sean T. H. Liu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 14
#2Hung-Mo Lin (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 24
Last. Nicole M. Bouvier (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 29
view all 30 authors...
219 CitationsSource
#1Dong Ji (Chinese PLA General Hospital)H-Index: 10
#2Dawei Zhang (Chinese PLA General Hospital)H-Index: 10
Last. Enqiang Qin (Chinese PLA General Hospital)H-Index: 12
view all 13 authors...
BACKGROUND: We aimed to clarify the high-risk factors with multivariate analysis and establish a prediction of disease progression, so as to help clinicians to better choose therapeutic strategy. METHODS: All the consecutive patients with COVID-19 admitted to Fuyang second people's hospital or the fifth medical center of Chinese PLA general hospital between January 20 and February 22, 2020, were enrolled and their clinical data were retrospectively collected. Multivariate COX regression was used...
252 CitationsSource
#1Michael J. Joyner (Mayo Clinic)H-Index: 93
#1Michael J. Joyner (Mayo Clinic)H-Index: 6
Last. R. Scott Wright (Mayo Clinic)H-Index: 55
view all 40 authors...
Objective To provide an update on key safety metrics after transfusion of convalescent plasma in hospitalized COVID-19 patients, having previously demonstrated safety in 5,000 hospitalized patients Patients and Methods From April 3 to June 2, 2020, the US FDA Expanded Access Program for COVID-19 convalescent plasma transfused a convenience sample of 20,000 hospitalized patients with COVID-19 convalescent plasma Results The incidence of all serious adverse events was low;these included transfusio...
179 CitationsSource
#1Fan Zhang (HIT: Harbin Institute of Technology)H-Index: 26
#2Rui Gan (HIT: Harbin Institute of Technology)H-Index: 1
Last. Zhiwei Huang (HIT: Harbin Institute of Technology)H-Index: 47
view all 12 authors...
The global Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has affected more than eight million people. There is an urgent need to investigate how the adaptive immunity is established in COVID-19 patients. In this study, we profiled adaptive immune cells of PBMCs from recovered COVID-19 patients with varying disease severity using single-cell RNA and TCR/BCR V(D)J sequencing. The sequencing data revealed SARS-CoV-2-specific shuffling of adaptive immune repertories and COVID-19-...
51 CitationsSource
#1Michael J. Joyner (Mayo Clinic)H-Index: 93
#2Jonathon W. Senefeld (Mayo Clinic)H-Index: 14
Last. Arturo Casadevall (Johns Hopkins University)H-Index: 137
view all 38 authors...
Importance: Passive antibody transfer is a longstanding treatment strategy for infectious diseases that involve the respiratory system. In this context, human convalescent plasma has been used to treat coronavirus disease 2019 (COVID-19), but the efficacy remains uncertain. Objective: To explore potential signals of efficacy of COVID-19 convalescent plasma. Design: Open-label, Expanded Access Program (EAP) for the treatment of COVID-19 patients with human convalescent plasma. Setting: Multicente...
187 CitationsSource
#1Ling Li (Peking Union Medical College)H-Index: 18
#2Wei Zhang ('SMMU': Second Military Medical University)H-Index: 2
Last. Zhong Liu (Peking Union Medical College)H-Index: 12
view all 34 authors...
Importance Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed. Objective To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19. Design, Setting, and Participants Open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28,...
667 CitationsSource
#2Peter HorbyH-Index: 67
#3Wei Shen LimH-Index: 37
Last. Martin J LandrayH-Index: 52
view all 26 authors...
BACKGROUND: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. METHODS: In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care...
3,101 CitationsSource
#1Feng Pan (HUST: Huazhong University of Science and Technology)H-Index: 5
#2Chuansheng Zheng (HUST: Huazhong University of Science and Technology)H-Index: 3
Last. Lian Yang (HUST: Huazhong University of Science and Technology)H-Index: 8
view all 8 authors...
This study aimed to compare the chest computed tomography (CT) findings between survivors and non-survivors with Coronavirus Disease 2019 (COVID-19). Between 12 January 2020 and 20 February 2020, the records of 124 consecutive patients diagnosed with COVID-19 were retrospectively reviewed and divided into survivor (83/124) and non-survivor (41/124) groups. Chest CT findings were qualitatively compared on admission and serial chest CT scans were semi-quantitively evaluated between two groups usin...
13 CitationsSource
Cited By6
#1Chiraphat Kloypan (Charité)H-Index: 3
Last. Pajaree Mongkhon (CMU: Chiang Mai University)H-Index: 3
view all 5 authors...
BACKGROUND: There is still a lack of consensus on the efficacy of convalescent plasma (CP) treatment in COVID-19 patients. We performed a systematic review and meta-analysis to investigate the efficacy of CP vs standard treatment/non-CP on clinical outcomes in COVID-19 patients. METHODS: Cochrane Library, PubMed, EMBASE and ClinicalTrials.gov were searched from December 2019 to 16 July 2021, for data from clinical trials and observational studies. The primary outcome was all-cause mortality. Ris...
2 CitationsSource
#1Paola de CandiaH-Index: 26
Last. Giuseppe MatareseH-Index: 70
view all 9 authors...
The clinical benefit of convalescent plasma for COVID-19 patients is still debated. In this systematic review and meta-analysis, we selected 10 randomized clinical trials (RCTs) and 15 non-randomized studies (total number of patients = 22,591) of convalescent plasma treatment and evaluated two different scenarios: 1- disease stage of plasma recipients and 2 - donated plasma antibody titer, considering all-cause mortality at the latest follow-up. Our results show that, when provided at early stag...
#1Kimia Honarmand (UWO: University of Western Ontario)H-Index: 8
#2Jeremy Penn (McMaster University)H-Index: 1
Last. Shannon M. Fernando (U of O: University of Ottawa)H-Index: 17
view all 19 authors...
OBJECTIVE: To describe the characteristics of Covid-19 randomized clinical trials (RCTs) and examine the association between trial characteristics and the likelihood of finding a significant effect. STUDY DESIGN: We conducted a systematic review to identify RCTs (up to October 21, 2020) evaluating drugs or blood products to treat or prevent Covid-19. We extracted trial characteristics (number of centers, funding sources, and sample size) and assessed risk of bias (RoB) using the Cochrane RoB 2.0...
#1Tejpal Gupta (HBNI: Homi Bhabha National Institute)H-Index: 8
#2Sadhana Kannan (HBNI: Homi Bhabha National Institute)H-Index: 20
Last. Prafulla Thakkar (HBNI: Homi Bhabha National Institute)
view all 4 authors...
Background null Despite scientific advances, there is no effective medical therapy for coronavirus disease 2019 (COVID-19). This systematic review and meta-analysis aimed to evaluate the safety and efficacy of convalescent plasma therapy in COVID-19. null Methods null This review was carried out in accordance with Cochrane methodology including risk of bias assessment and grading of the quality of evidence. Only prospective clinical trials randomly assigning COVID-19 patients to convalescent pla...
2 CitationsSource
#1Kelly Cho (VA: United States Department of Veterans Affairs)
#2Sarah C Keithly (VA: United States Department of Veterans Affairs)
Last. Yuk-Lam Ho (VA: United States Department of Veterans Affairs)H-Index: 10
view all 24 authors...
Background null Early convalescent plasma transfusion may reduce mortality in patients with non-severe coronavirus disease 2019 (COVID-19). null Methods null This study emulates a (hypothetical) target trial using observational data from a cohort of United States Veterans admitted to a Department of Veterans Affairs (VA) facility between May 1 and November 17, 2020 with non-severe COVID-19. The intervention was convalescent plasma initiated within 2 days of eligibility. Thirty-day mortality was ...
#1Sixten Körper (University of Ulm)H-Index: 6
#1Sixten Koerper (University of Ulm)H-Index: 1
Last. Hubert Schrezenmeier (University of Ulm)H-Index: 78
view all 27 authors...
Rationale: COVID-19 convalescent plasma (CCP) has been considered a treatment option in COVID-19. Objectives:: To assess the efficacy of neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19 requiring respiratory support or intensive care treatment. Methods: Patients (n=105) were randomized 1:1 to either receive standard treatment and 3 units of CCP or standard treatment alone. Control group patients with progress on day 14 could cross over to the CCP group. Primary...
2 CitationsSource
#1Vasiliki Pappa (UoA: National and Kapodistrian University of Athens)H-Index: 14
#2Anthi Bouchla (UoA: National and Kapodistrian University of Athens)H-Index: 6
Last. Meletios A. Dimopoulos (UoA: National and Kapodistrian University of Athens)H-Index: 145
view all 30 authors...
COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (n = 59) to a control group (n = 59). Sixty patients received CP within a median time of 7 days from sy...
1 CitationsSource